Stock indexes on Monday recovered from early losses and settled higher. Strength in chip stocks led the broader market higher on Monday.  Also, energy producers rallied after the price of WTI crude ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Vera Therapeutics (NASDAQ:VERA) shares surged 64% after positive late-stage trial results for atacicept in treating IgA ...

Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in ...

Vera Therapeutics shares jumped in premarket trading Monday after the company said that its treatment for chronic kidney disease, also known as Berger's disease, has shown positive results in its ...

H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $85 from $75 and keeps a Buy rating on the shares. The company ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has unveiled six innovative medical technologies and transferred them to various companies for commercialisation, ...

Therapeutic plasma exchange combined with intravenous immunoglobulin reduced biological age on average by 2.6 years, as ...

Luke Pickering brushed off tingling in his hands and feet as pins and needles but it turned out to be a rare condition that ...

I was paralyzed from the head down. Even my face was paralyzed,” recalled 31-year-old Luke Pickering of England ...